Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6011007 | NOVO NORDISK INC | Acylated insulin |
Feb, 2014
(10 years ago) | |
US6869930 | NOVO NORDISK INC | Acylated insulin |
Feb, 2014
(10 years ago) | |
US5866538 | NOVO NORDISK INC | Insulin preparations containing NaCl |
Jun, 2017
(6 years ago) | |
US5750497 | NOVO NORDISK INC | Acylated insulin |
Jun, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-117) | May 18, 2015 |
M(M-115) | Apr 06, 2015 |
Market Authorisation Date: 31 October, 2013
Treatment: Levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus
Dosage: INJECTABLE;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6869930 | NOVO NORDISK INC | Acylated insulin |
Feb, 2014
(10 years ago) | |
US6011007 | NOVO NORDISK INC | Acylated insulin |
Feb, 2014
(10 years ago) | |
US5866538 | NOVO NORDISK INC | Insulin preparations containing NaCl |
Jun, 2017
(6 years ago) | |
US6004297 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(5 years ago) | |
USRE43834 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(5 years ago) | |
US5750497 | NOVO NORDISK INC | Acylated insulin |
Jun, 2019
(4 years ago) | |
USRE41956 | NOVO NORDISK INC | Dose setting limiter |
Jan, 2021
(3 years ago) | |
US9265893 | NOVO NORDISK INC | Injection button |
Sep, 2032
(8 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-117) | May 18, 2015 |
M(M-115) | Apr 06, 2015 |
Market Authorisation Date: 31 October, 2013
Treatment: Levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus
Dosage: INJECTABLE;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5750497 | NOVO NORDISK INC | Acylated insulin |
Jun, 2019
(4 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5866538 | NOVO NORDISK INC | Insulin preparations containing NaCl |
Jun, 2017
(6 years ago) | |
US6899699 | NOVO NORDISK INC | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
US9486588 | NOVO NORDISK INC | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
US8672898 | NOVO NORDISK INC | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
US8579869 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(10 months ago) | |
US7762994 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(17 days from now) | |
US8684969 | NOVO NORDISK INC | Injection device with torsion spring and rotatable display |
Oct, 2025
(1 year, 5 months from now) | |
US9861757 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 8 months from now) | |
US9108002 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 8 months from now) | |
US9616180 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 8 months from now) | |
US10376652 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 8 months from now) | |
US10357616 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 8 months from now) | |
US8920383 | NOVO NORDISK INC | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(2 years from now) | |
US9775953 | NOVO NORDISK INC | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(2 years from now) | |
US10220155 | NOVO NORDISK INC | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(2 years from now) | |
US7686786 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Aug, 2026
(2 years from now) | |
USRE46363 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Aug, 2026
(2 years from now) | |
US9687611 | NOVO NORDISK INC | Injection device with torsion spring and rotatable display |
Feb, 2027
(2 years from now) | |
US9457154 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Sep, 2027
(3 years from now) | |
US9132239 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Feb, 2032
(7 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-117) | May 18, 2015 |
M(M-115) | Apr 06, 2015 |
Market Authorisation Date: 31 October, 2013
Treatment: Levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus
Dosage: INJECTABLE;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6869930 | NOVO NORDISK INC | Acylated insulin |
Feb, 2014
(10 years ago) | |
US6011007 | NOVO NORDISK INC | Acylated insulin |
Feb, 2014
(10 years ago) | |
US5866538 | NOVO NORDISK INC | Insulin preparations containing NaCl |
Jun, 2017
(6 years ago) | |
US5750497 | NOVO NORDISK INC | Acylated insulin |
Jun, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-117) | May 18, 2015 |
M(M-115) | Apr 06, 2015 |
Market Authorisation Date: 31 October, 2013
Treatment: Levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus
Dosage: INJECTABLE;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6869930 | NOVO NORDISK INC | Acylated insulin |
Feb, 2014
(10 years ago) | |
US6011007 | NOVO NORDISK INC | Acylated insulin |
Feb, 2014
(10 years ago) | |
US5866538 | NOVO NORDISK INC | Insulin preparations containing NaCl |
Jun, 2017
(6 years ago) | |
US5750497 | NOVO NORDISK INC | Acylated insulin |
Jun, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-117) | May 18, 2015 |
M(M-115) | Apr 06, 2015 |
Market Authorisation Date: 31 October, 2013
Treatment: Levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus
Dosage: INJECTABLE;SUBCUTANEOUS